-
公开(公告)号：US09056135B2
公开(公告)日：2015-06-16
申请号：US13478408
申请日：2012-05-23
Applicant: Ethan Dmitrovsky , Xi Liu , Sarah Freemantle , Lorenzo F. Sempere , Charles Cole , Sakari Kauppinen , Mads Bak , Mette Christensen
Inventor： Ethan Dmitrovsky , Xi Liu , Sarah Freemantle , Lorenzo F. Sempere , Charles Cole , Sakari Kauppinen , Mads Bak , Mette Christensen
IPC: C07H21/04 , A61K45/06 , C12N15/11 , C12N15/113 , C12Q1/68 , A61K31/7105
CPC classification number: A61K45/06 , A61K31/7105 , C12N15/111 , C12N15/113 , C12N2310/14 , C12N2310/141 , C12N2320/12 , C12Q1/6886 , C12Q2600/106 , C12Q2600/178
Abstract: The present invention relates to novel molecular markers for diagnosis and classification of human breast cancer and lung cancer.
Abstract translation: 本发明涉及用于人乳腺癌和肺癌诊断和分类的新型分子标志物。
-
公开(公告)号：US20130295578A1
公开(公告)日：2013-11-07
申请号：US13978724
申请日：2012-01-10
Applicant: Lorenzo F. Sempere , Murray Korc
Inventor： Lorenzo F. Sempere , Murray Korc
IPC: G01N33/50
CPC classification number: G01N33/5008 , G01N33/5011 , G01N33/5088
Abstract: The present invention includes methods for screening for drug resistance in cancer tissue ex vivo which comprises a novel 3-dimensional cell culture system that mimics the tumor microenvironment.
Abstract translation: 本发明包括用于在体外筛选癌组织中耐药性的方法，其包括模拟肿瘤微环境的新型三维细胞培养系统。
-
公开(公告)号：US20160083472A1
公开(公告)日：2016-03-24
申请号：US14686422
申请日：2015-04-14
Applicant: Randolph J. Noelle , Li Wang , Thomas Broughton , Lorenzo F. Sempere , Janet Louise Lines
Inventor： Randolph J. Noelle , Li Wang , Thomas Broughton , Lorenzo F. Sempere , Janet Louise Lines
IPC: C07K16/28 , A61K39/395 , A61K39/00 , C07K16/30 , A61K45/06
CPC classification number: C07K16/2827 , A61K38/00 , A61K39/00 , A61K39/0005 , A61K39/3955 , A61K45/06 , A61K2039/505 , A61K2039/507 , A61K2039/57 , A61P35/00 , A61P37/00 , C07K7/08 , C07K16/30 , C07K16/3015 , C07K16/3023 , C07K2317/75 , C07K2317/76
Abstract: The present invention is directed to synergic or additive therapies comprising the administration of a VISTA antagonist and a PD-1, PD-L1 or POD-L3 antagonist; or the combination of a VISTA agonist and a -1, PD-L1 or POD-L3 agonist which combinations respectively elicit an additive or synergistic effect at promoting T cell immunity or inhibiting T cell immunity, i.e., CD4, CD8 or Th1 immunity. The agonists and antagonists may be in the same or separate compositions and may be administered together or separately administered in either order.
Abstract translation: 本发明涉及包括施用VISTA拮抗剂和PD-1，PD-L1或POD-L3拮抗剂的协同或添加剂疗法; 或VISTA激动剂和-1，PD-L1或POD-L3激动剂的组合，其组合分别在促进T细胞免疫或抑制T细胞免疫（即CD4，CD8或Th1免疫）方面引起添加剂或协同效应。 激动剂和拮抗剂可以在相同或分开的组合物中，并且可以一起施用或以任何顺序分开施用。
-
Patent Agency Ranking
4.发明授权Methods for determining response to neoadjuvant therapy and survival using MicroRNA-10b 有权使用MicroRNA-10b测定新辅助治疗和存活的反应的方法公开(公告)号：US08580513B2
公开(公告)日：2013-11-12
申请号：US13172047
申请日：2011-06-29
Applicant: Lorenzo F. Sempere , Murray Korc , Meir Preis
Inventor： Lorenzo F. Sempere , Murray Korc , Meir Preis
IPC: C12Q1/68
CPC classification number: C12Q1/6886 , C12Q1/6841 , C12Q2600/158 , C12Q2600/178 , C12Q2525/207 , C12Q2563/131
Abstract: The present invention provides methods for determining response to neoadjuvant therapy and metastasis-free survival in pancreatic ductal adenocarcinoma based upon the level of microRNA expression and optionally the presence of a protein cancer cell marker in biological samples such as formalin-fixed paraffin-embedded specimens using in situ hybridization and optionally an immunohistochemical assay.
Abstract translation: 本发明提供了基于微小RNA表达水平和任选地在诸如福尔马林固定的石蜡包埋样品中的蛋白质癌细胞标记物的存在来确定胰腺导管腺癌中新辅助治疗和无转移生存的响应的方法，所述生物样品使用 原位杂交和任选的免疫组织化学测定。
-
公开(公告)号：US20130296399A1
公开(公告)日：2013-11-07
申请号：US13478408
申请日：2012-05-23
Applicant: Ethan Dmitrovsky , Xi Liu , Sarah Freemantle , Lorenzo F. Sempere , Charles Cole , Sakari Kauppinen , Mads Bak , Mette Christensen
Inventor： Ethan Dmitrovsky , Xi Liu , Sarah Freemantle , Lorenzo F. Sempere , Charles Cole , Sakari Kauppinen , Mads Bak , Mette Christensen
IPC: C12Q1/68 , A61K45/06 , A61K31/7105
CPC classification number: A61K45/06 , A61K31/7105 , C12N15/111 , C12N15/113 , C12N2310/14 , C12N2310/141 , C12N2320/12 , C12Q1/6886 , C12Q2600/106 , C12Q2600/178
Abstract: The present invention relates to novel molecular markers for diagnosis and classification of human breast cancer and lung cancer.
Abstract translation: 本发明涉及用于诊断和分类人乳腺癌和肺癌的新型分子标志物。
-
6.发明申请Methods for Determining Response to Neoadjuvant Therapy and Survival Using MicroRNA-10b 有权使用MicroRNA-10b测定新辅助治疗和存活反应的方法公开(公告)号：US20120021415A1
公开(公告)日：2012-01-26
申请号：US13172047
申请日：2011-06-29
Applicant: Lorenzo F. Sempere , Murray Korc , Meir Preis
Inventor： Lorenzo F. Sempere , Murray Korc , Meir Preis
IPC: C12Q1/68
CPC classification number: C12Q1/6886 , C12Q1/6841 , C12Q2600/158 , C12Q2600/178 , C12Q2525/207 , C12Q2563/131
Abstract: The present invention provides methods for determining response to neoadjuvant therapy and metastasis-free survival in pancreatic ductal adenocarcinoma based upon the level of microRNA expression and optionally the presence of a protein cancer cell marker in biological samples such as formalin-fixed paraffin-embedded specimens using in situ hybridization and optionally an immunohistochemical assay.
Abstract translation: 本发明提供了基于微小RNA表达水平和任选地在诸如福尔马林固定的石蜡包埋样品中的蛋白质癌细胞标记物的存在来确定胰腺导管腺癌中新辅助治疗和无转移生存的响应的方法，所述生物样品使用 原位杂交和任选的免疫组织化学测定。
-
公开(公告)号：US20180237525A9
公开(公告)日：2018-08-23
申请号：US14686422
申请日：2015-04-14
Applicant: Randolph J. Noelle , Li Wang , Thomas Broughton , Lorenzo F. Sempere , Janet Louise Lines
Inventor： Randolph J. Noelle , Li Wang , Thomas Broughton , Lorenzo F. Sempere , Janet Louise Lines
IPC: C07K16/28 , C07K16/30 , A61K45/06 , A61K39/00 , A61K39/395
CPC classification number: C07K16/2827 , A61K38/00 , A61K39/00 , A61K39/0005 , A61K39/3955 , A61K45/06 , A61K2039/505 , A61K2039/507 , A61K2039/57 , A61P35/00 , A61P37/00 , C07K7/08 , C07K16/30 , C07K16/3015 , C07K16/3023 , C07K2317/75 , C07K2317/76
Abstract: The present invention is directed to synergic or additive therapies comprising the administration of a VISTA antagonist and a PD-1, PD-L1 or POD-L3 antagonist; or the combination of a VISTA agonist and a -1, PD-L1 or POD-L3 agonist which combinations respectively elicit an additive or synergistic effect at promoting T cell immunity or inhibiting T cell immunity, i.e., CD4, CD8 or Th1 immunity. The agonists and antagonists may be in the same or separate compositions and may be administered together or separately administered in either order.
-
公开(公告)号：US20140147838A1
公开(公告)日：2014-05-29
申请号：US13811010
申请日：2011-06-16
Applicant: Lorenzo F. Sempere , Murray Korc
Inventor： Lorenzo F. Sempere , Murray Korc
IPC: C12Q1/68
CPC classification number: C12Q1/6886 , C12Q1/6841 , C12Q2600/158 , C12Q2600/178 , C12Q2525/207 , C12Q2563/131
Abstract: The present invention is directed to systems and methods of conducting a purchase transaction of eligible goods or services using a stored value associated with an indicia. Methods in accordance with the invention may include steps
Abstract translation: 本发明涉及使用与标记相关联的存储值进行合格商品或服务的购买交易的系统和方法。 根据本发明的方法可以包括步骤
-
-
-
-
-
-
-
Search Results
8
records
(took 0.018 seconds)
